𝔖 Bobbio Scriptorium
✦   LIBER   ✦

TP53 mutation in colorectal cancer

✍ Scribed by Barry Iacopetta

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
125 KB
Volume
21
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis

Approximately half of all colorectal cancers show p53 (TP53) gene mutations, with higher frequencies observed in distal colon and rectal tumors and lower frequencies in proximal tumors and those with the microsatellite instability or methylator phenotypes. Alterations to this gene appear to have little or no prognostic value for colorectal cancer patients treated by surgery alone, but are associated with worse survival for patients treated with chemotherapy. There is some evidence that different p53 mutations are associated with different clinical features including prognosis and response to therapy, although further large studies are required to confirm this. Several in vitro, animal and clinical studies have shown that normal p53 is required for the response of colorectal cancers to 5-fluorouracil-based chemotherapy. This should be confirmed by additional retrospective cohort studies and by the incorporation of P53 status in ongoing and future clinical trials. The evaluation of p53 overexpression, using a standardized immunohistochemical (IHC) procedure, could be a clinically useful marker for the identification of colorectal cancer patients likely to benefit from the standard chemotherapy regime currently used for this disease.

πŸ“œ SIMILAR VOLUMES

Impact of GSTT1, GSTM1, GSTP1 and NAT2 g
Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer
✍ Jean-Marc Ferraz; Franck ZinzindohouΓ©; Thierry Lecomte; Paul-Henri Cugnenc; Mari πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 92 KB

## Abstract Which carcinogens are of influence in the development of human colorectal cancers remains a question; one answer could be the finding that specific polymorphisms in xenobiotic metabolizing enzymes are related to particular mutations in cancer genes. __KRAS2__ and __TP53__ gene mutations

TP53 mutations in human skin cancers
TP53 mutations in human skin cancers
✍ Giuseppina Giglia-Mari; Alain Sarasin πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 444 KB

The p53 gene (TP53) is mutated in numerous human cancers. We have used it as a molecular target to characterize the induction of mutations in human skin cancers. About 50% of all skin cancers in normal individuals exhibit p53 mutations. This frequency rises to 90% in skin cancers of patients with th

TP53 mutations in familial breast cancer
TP53 mutations in familial breast cancer: Functional aspects
✍ Milena Gasco; Isik G Yulug; Tim Crook πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 112 KB

Mutation in p53 (TP53) remains one of the most commonly described genetic events in human neoplasia. The occurrence of mutations is somewhat less common in sporadic breast carcinomas than in other cancers, with an overall frequency of about 20%. There is, however, evidence that p53 is mutated at a s

TP53 gene mutations in plasma DNA of can
TP53 gene mutations in plasma DNA of cancer patients
✍ Jose M. Silva; Rocio Gonzalez; Gemma Dominguez; Jose M. Garcia; Pilar EspaΓ±a; Fe πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

Using different molecular techniques, DNA has been shown to be present in plasma of patients with several types of tumors. Mutations of TP53 are the most common genetic changes in human cancers. We investigated the presence of TP53 gene mutations in plasma DNA of breast and small cell lung cancer pa